龙源期刊网 http://www.qikan.com.cn 罗沙司他胶囊与重组人促红素治疗肾性贫血 的效果及预后比较 作者:李宏彬 梁军 马强 来源:《中国医药导报》2020 年第 08 期 龙源期刊网 http://www.qikan.com.cn [摘要] 目的 探讨罗沙司他胶囊与重组人促红素(rhEPO)治疗维持性血液透析(MHD) 患者肾性贫血的效果及预后。 方法 选取 2019 年 7~10 月北京市东城区第一人民医院收治的 56 例 MHD 肾性贫血患者为研究对象,依据随机数字表法将其分为对照组与研究组,每组各 28 例。两组均使用琥珀亚酸铁,对照组在此基础上使用 rhEPO 进行治疗,研究组则使用罗沙 司他胶囊进行治疗,治疗 3 个月。比较两组治疗前及治疗 3 个月后贫血指标[红细胞计数 (RBC)、血红蛋白(Hb)、血细胞比容(Hct)]、铁代谢指标[血清铁蛋白(SF)、转铁蛋 白饱和度(TSAT)、转铁蛋白(TRF)、铁调素(Hepc)],并记录不良反应发生情况。 结果 两组治疗前 RBC、Hb、Hct 水平比较,差异无统计学意义(P > 0.05)。治疗 3 个月后, RBC、Hb、Hct 水平高于治疗前,且研究组高于对照组,差异均有统计学意义(均 P < 0.05)。两组治疗前 SF、TSAT、TRF、Hepc 水平比较,差异无统计学意义(P > 0.05)。治疗 3 个月后,两组 SF、TSAT、TRF 水平高于治疗前,两组 Hepc 水平低于治疗前,研究组 SF、 TSAT、TRF 高于对照组,Hepc 水平低于对照组,差异均有统计学意义(均 P < 0.05)。研究 组不良反应发生率低于对照组,差异有统计学意义(P < 0.05)。结论 与 rhEPO 比较,罗沙司 他胶囊治疗 MHD 肾性贫血效过更佳,可显著纠正贫血症状,增加机体对铁的利用率,安全性 较高,有较高的应用价值。 [关键词] 肾性贫血;罗沙司他胶囊;重组人促红素 [中图分类号] R97; ; ; ; ; [文献标识码] A; ; ; ; ; [文章编号] 1673-7210(2020)03(b)-017804 [Abstract] Objective To investigate the efficacy and prognosis of Roxadustat Capsules and recombinant human erythropoietin (rhEPO) in the treatment of maintenance hemodialysis (MHD) with renal anemia. Methods A total of 56 cases with MHD renal anemia who admitted to Beijing East District First People′s Hospital from July to October 2019 were selected as the subjects. They were divided into control group and study group by random number table method, with 28 cases in each group. Two groups were treated with Ferrous Succinate Tablets orally, and control group was treated with rhEPO, while study group was treated with Roxadustat Capsules. They were treated for 3 months. Anemia indicators [red blood cell count (RBC), hemoglobin (Hb), 龙源期刊网 http://www.qikan.com.cn hematocrit (Hct)] and iron metabolism indexes [serum ferritin (SF), transferrin saturation (TSAT), transferrin (TRF), hepcidin (Hepc)] were compared between two groups before and after 3 months of treatment, and the adverse reactions were recorded. Results There was no significant difference in the levels of RBC, Hb and Hct between two groups before treatment(P > 0.05);after 3 months of treatment, the levels of RBC, Hb, Hct were significantly higer than those before treatment, and study group was higher than control group, and the differences were statistically significant(all P < 0.05). There was no significant difference in the levels of SF, TSAT, TRF and Hepc between two groups before treatment(P > 0.05). After 3 months of treatment, the levels of SF, TSAT an TRF were significantly higer than th